Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03635983 · ClinicalTrials.gov registry record · Phase 3
A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma
A Phase 3 study of Melanoma, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 783
- Enrollment target
- 20
- Study locations
NCT03635983 is a Phase 3 study of Melanoma that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 783 participants, above the 704-participant average among 266 other Melanoma trials with a reported enrollment target (11% higher). The trial reports 20 study locations across 15 states.
The verdict
NCT03635983, a Phase 3 study of Melanoma, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 783 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to test the effectiveness (how well the drug works), safety, and tolerability of the investigational drug called NKTR-214, when combined with nivolumab versus nivolumab given alone in participants with previously untreated melanoma skin cancer that is either unable to be surgically removed or has spread
Conditions Studied
Interventions
- BIOLOGICAL Nivolumab
- BIOLOGICAL NKTR-214
Study Locations (20)
Florida
- Local Institution - 0153 - Miami
- Local Institution - 0017 - Miami Beach
- Local Institution - 0112 - Tampa
California
- Local Institution - 0014 - La Jolla
- Local Institution - 0122 - Stanford
New Jersey
- Local Institution - 0016 - Hackensack
- Local Institution - 0185 - New Brunswick
Oregon
- Local Institution - 0011 - Portland
- Local Institution - 0013 - Portland
Arizona
- Local Institution - 0187 - Tucson
Colorado
- Local Institution - 0051 - Aurora
Connecticut
- Local Institution - 0065 - New Haven
Georgia
- Local Institution - 0012 - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 783 participants |
| Start Date | 2018-09-21 |
| Est. Completion | 2024-03-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03635983
The ClinicalTrials.gov registry entry for NCT03635983 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 783 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 704-participant average among 266 other Melanoma trials with a reported enrollment target (11% higher). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab is the first listed.
NCT03635983 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Florida, California, New Jersey.
Frequently Asked Questions
What is clinical trial NCT03635983 about?
NCT03635983 is a clinical study titled "A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma". The purpose of the study is to test the effectiveness (how well the drug works), safety, and tolerability of the investigational drug called NKTR-214, when combined with nivolumab versus nivolumab given alone in participants with previously untreated melanoma skin cancer that is either unable to be ...
What is the current status of trial NCT03635983?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 783 participants. The study started on 2018-09-21. Estimated completion is 2024-03-19.
What conditions does trial NCT03635983 study?
This clinical trial studies the following conditions: Melanoma.
What interventions are being tested in trial NCT03635983?
The interventions under investigation include: Nivolumab (BIOLOGICAL), NKTR-214 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03635983?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03635983 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
RECRUITING · Phase 3
-
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
RECRUITING · Phase 3
-
Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy
ACTIVE NOT RECRUITING · Phase 3
-
A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
ACTIVE NOT RECRUITING · Phase 3
-
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
ACTIVE NOT RECRUITING · Phase 3
-
Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.